Physician profile
Caitlin Elmore
NPI 1063909711
$2,551.71
in general payments reported to CMS, 2019-2025
27 companies · $974 in 2025
The $974 reported for 2025 was more than what 91% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.41 · 2021: $48.42 · 2022: $23.90 · 2023: $432 · 2024: $991 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $337.87 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $304.23 | 2023-2025 | |
| Pfizer INC. | $244.94 | 2024-2025 | |
| Novo Nordisk INC | $218.57 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $197.02 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $191.62 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $159.26 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $144.94 | 2023-2025 | Veozah |
| Noven Therapeutics, LLC | $116.87 | 2024 | Xelstrym |
| Regeneron Healthcare Solutions, INC. | $92.77 | 2023-2025 | Dupixent |
| Dexcom, INC. | $88.10 | 2024-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $72.38 | 2023 | Venaseal, Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.52 | 2023-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $48.42 | 2021 | |
| Exact Sciences Corporation | $45.87 | 2023-2025 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $30.87 | 2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $29.53 | 2025 | Shingrix, Bexsero, Arexvy |
| Nalu Medical, INC. | $22.05 | 2025 | Nalu Neurostimulation System |
| Eisai INC. | $19.67 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $19.54 | 2025 | Rexulti |
| Agile Therapeutics, INC. | $18.08 | 2024 | Twirla |
| Philips North America LLC | $15.69 | 2024 | (Ak6) Vest Therapy |
| Phathom Pharmaceuticals, INC. | $15.55 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.20 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $13.78 | 2025 | Nexletol |
| Tonix Medicines, INC. | $13.53 | 2025 | Tonmya |
| Biohaven Pharmaceutical Holding Company LTD. | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Elmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.